Purpose There is no optimal prognostic model for T-cell lymphoblastic lymphoma (T-LBL). Here, we discussed the predictive value of total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) measured on 18F-fluorodeoxyglucose positron emission tomography–computed tomography (PET-CT) in T-LBL.
Materials and Methods Thirty-seven treatment naïve T-LBL patients with PET-CT scans were enrolled. TMTV was obtained using the 41% maximum standardized uptake value (SUVmax) threshold method, and TLG was measured as metabolic tumor volume multiplied by the mean SUV. Progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier curves and compared by the log-rank test.
Results The optimal cutoff values for SUVmax, TMTV, and TLG were 12.7, 302 cm3, and 890, respectively. A high SUVmax, TMTV, and TLG indicated a shorten PFS and OS. On multivariable analysis, TMTV ≥ 302 cm3, and central nervous system (CNS) involvement predicted inferior PFS, while high SUVmax, TLG and CNS involvement were associated with worse OS. Subsequently, we generated a risk model comprising high SUVmax, TMTV or TLG and CNS involvement, which stratified the population into three risk groups, which had significantly different median PFS of not reached, 14 months, and 7 months for low-risk group, mediate-risk group, and high-risk group, respectively (p < 0.001). Median OS were not reached, 27 months, and 13 months, respectively (p < 0.001).
Conclusion Baseline SUVmax, TMTV, and TLG measured on PET-CT are strong predictors of worse outcome in T-LBL. A risk model integrating these three parameters with CNS involvement identifies patients at high risk of disease progression.
Citations
Citations to this article as recorded by
A novel prognostic model utilizing TMTV and SUVmax from 18F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma Hua Wang, Demei Feng, Yiwen Mo, Huangming Hong, Yingying Hu, Li Huang, Xiaolei Wei, Yajun Li, Haibin Huang, Runhui Zheng, Yonghua Li, Hui Zeng, Robert Peter Gale, Tian Ying, Jing Guo, Zhenshu Xu, Wei Fan, Tongyu Lin BMC Cancer.2025;[Epub] CrossRef
Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma Hazim S. Ababneh, Andrea K. Ng, Jeremy S. Abramson, Jacob D. Soumerai, Ronald W. Takvorian, Matthew J. Frigault, Chirayu G. Patel Hematological Oncology.2024;[Epub] CrossRef
Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [
18
F]FDG-PET/CT and bone marrow biopsy findings
Xinyu Liang, Chunli Yang, Minggang Su, Liqun Zou Current Medical Research and Opinion.2024; 40(5): 803. CrossRef
The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection Xia Lu, Ang Wei, Xu Yang, Jun Liu, Siqi Li, Ying Kan, Wei Wang, Tianyou Wang, Rui Zhang, Jigang Yang Frontiers in Medicine.2022;[Epub] CrossRef
Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma Fei Liu, Bingxin Gu, Nan Li, Herong Pan, Wen Chen, Ying Qiao, Shaoli Song, Xiaosheng Liu Frontiers in Oncology.2022;[Epub] CrossRef
Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT Kwai Han Yoo Blood Research.2022; 57(S1): S75. CrossRef
Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT Hongyan Li, Min Wang, Yajing Zhang, Fan Hu, Kun Wang, Chenyang Wang, Zairong Gao Frontiers in Oncology.2022;[Epub] CrossRef
PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T‐Cell Lymphoblastic Lymphoma Jin Zhao, Xiaojing Guo, Li Ma, Meijing Zheng, Tao Guan, Liping Su, Mohammad Farukh Hashmi Contrast Media & Molecular Imaging.2022;[Epub] CrossRef
Clinical and prognostic role of 2-[18F]FDG PET/CT and sarcopenia in treatment-naïve patients with T-cell lymphoblastic lymphoma Xiaoyue Tan, Hui Yuan, Dongjiang Li, Xiaolin Sun, Chongyang Ding, Lei Jiang Annals of Hematology.2022; 101(12): 2699. CrossRef
Prognostic value of baseline total metabolic tumour volume of 18F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma Huanyu Gong, Tiannv Li, Jianyong Li, Lijun Tang, Chongyang Ding EJNMMI Research.2021;[Epub] CrossRef
Purpose
The purpose of this study was to investigate the prognostic significance of total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) in patients with follicular lymphoma (FL) at baseline and mid-treatment with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) scans.
Methods
The study analyzed data from 48 patients with FL who were treated in Jiangsu Province Hospital and reviewed their baseline PET-CT scans. TMTV and TLG were computed by using the absolute value of 2.0, 2.5, and 3.0 thresholding method, respectively.
Results
Median age was 53 years, 75.0% of patients had stage III to IV disease, 43.8% had a Follicular Lymphoma International Prognostic Index 1 (FLIPI1) score of 3 to 5 and 20.8% had a FLIPI2 score of 3 to 5. Receiver operating characteristic (ROC) curve analysis showed the optimal cut-off values for TMTV3.0 and TLG3.0 were 476.4 (sensitivity, 85.7%; specificity, 78.0%; area under the curve [AUC], 0.760; p=0.003) and 2,676.9 (sensitivity, 71.4%; specificity, 78.0%; AUC, 0.760; p=0.003). On multivariable analysis, TMTV3.0 and TLG3.0 were independent predictors of both progression-free survival (PFS) (hazard ratio [HR], 5.406; 95% confidence interval [CI], 1.326 to 22.040; p=0.019 and HR, 6.502; 95% CI, 1.079 to 39.182; p=0.042) and overall survival (OS) (HR, 4.111; 95% CI, 1.125 to 15.027; p=0.033 and HR, 5.885; 95% CI, 1.014 to 34.148; p=0.049). ROC curve analysis showed the optimal cut-off values for ΔTMTV3.0 and ΔTLG3.0 were 66.3% (sensitivity, 85.7%; specificity, 63.4%; AUC, 0.774; p < 0.001) and 64.5% (sensitivity, 85.7%; specificity, 65.9%; AUC, 0.777; p < 0.001).
Conclusion
Baseline TMTV and TLG are strong predictors of PFS and OS in FL. Furthermore, interim TMTV (ΔTMTV > 66.3%) and TLG (ΔTLG > 64.5%) reduction are valuable tools for early treatment response assessment in FL patients.
Citations
Citations to this article as recorded by
Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy Nan Wang, Xin‐Yun Huang, Xu‐Feng Jiang, Li Wang, Shu Cheng, Peng‐Peng Xu, Lei Dong, Bin‐Shen Ou‐Yang, Rong‐Ji Mu, Chen Li, Yan Zhao, Yan Feng, Hong‐Jing Dou, Zhong Zheng, Wei‐Li Zhao Hematological Oncology.2025;[Epub] CrossRef
The Predictive Role of Baseline 18F-FDG PET/CT Radiomics in Follicular Lymphoma on Watchful Waiting: A Preliminary Study Daria Maccora, Michele Guerreri, Rosalia Malafronte, Francesco D’Alò, Stefan Hohaus, Marco De Summa, Vittoria Rufini, Roberto Gatta, Luca Boldrini, Lucia Leccisotti, Salvatore Annunziata Diagnostics.2025; 15(4): 432. CrossRef
Baseline [18F]FDG PET/CT radiomics for predicting interim efficacy in follicular lymphoma treated with first-line R-CHOP Zeying Wen, Xiaohe Gao, Qingxia Wu, Jianwei Yang, Jian Sun, Keliu Wu, Hongfei Zhao, Ruihua Wang, Yanmei Li BMC Cancer.2025;[Epub] CrossRef
A novel prognostic model utilizing TMTV and SUVmax from 18F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma Hua Wang, Demei Feng, Yiwen Mo, Huangming Hong, Yingying Hu, Li Huang, Xiaolei Wei, Yajun Li, Haibin Huang, Runhui Zheng, Yonghua Li, Hui Zeng, Robert Peter Gale, Tian Ying, Jing Guo, Zhenshu Xu, Wei Fan, Tongyu Lin BMC Cancer.2025;[Epub] CrossRef
Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma Shijia Cheng, Yanyan Liu Current Treatment Options in Oncology.2025; 26(4): 313. CrossRef
Personalised therapy in follicular lymphoma – is the dial turning? Kim M. Linton, Lena Specht, Astrid Pavlovsky, Carrie A. Thompson, Eva Kimby, Daphne de Jong, Loretta J. Nastoupil, Anne‐Ségolène Cottereau, Carla Casulo, Clémentine Sarkozy, Jessica Okosun Hematological Oncology.2024;[Epub] CrossRef
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial A.S. Cottereau, L. Rebaud, J. Trotman, P. Feugier, L.J. Nastoupil, E. Bachy, I.W. Flinn, C. Haioun, L. Ysebaert, N.L. Bartlett, H. Tilly, O. Casasnovas, R. Ricci, C. Portugues, I. Buvat, M. Meignan, F. Morschhauser Annals of Oncology.2024; 35(1): 130. CrossRef
Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma S. Draye-Carbonnier, V. Camus, S. Becker, D. Tonnelet, E. Lévêque, A. Zduniak, F. Jardin, H. Tilly, P. Vera, P. Decazes Scientific Reports.2024;[Epub] CrossRef
Baseline 18F-FDG PET/CT may contribute to the determination of initial treatment strategy for newly diagnosed follicular lymphoma Qiao Yang, Hongzhe Zhang, Yan Zhang, Wei Zhang, Daobin Zhou, Yaping Luo European Journal of Radiology.2024; 178: 111632. CrossRef
The value of semiquantitative PET features and end‐of‐therapy PET in grade 3B follicular lymphoma Allison Barraclough, Sze Ting Lee, Diego Villa, Greg Hapgood, Don Wilson, Geoffrey Chong, Eliza A. Hawkes British Journal of Haematology.2024; 205(6): 2254. CrossRef
Semiquantitative 2-[18F]FDG PET/CT-based parameters role in lymphoma Domenico Albano, Marco Ravanelli, Rexhep Durmo, Annibale Versari, Angelina Filice, Alessio Rizzo, Manuela Racca, Daniele Antonio Pizzuto, Francesco Bertagna, Salvatore Annunziata Frontiers in Medicine.2024;[Epub] CrossRef
Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation‐Wide cohort study Isabel Ródenas‐Quiñonero, Tzu Chen‐Liang, Taida Martín‐Santos, Antonio Salar, Marta Fernández‐González, Carolina Celades, José‐Tomás Navarro, Ana Belén Martínez‐Garcia, Rafael Andreu, Aitana Balaguer, Alejandro Martin García‐Sancho, Mónica Baile, Javier L Cancer Medicine.2023; 12(6): 6536. CrossRef
Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL) Yiting Xie, Yue Teng, Chong Jiang, Chongyang Ding, Zhengyang Zhou Japanese Journal of Radiology.2023; 41(7): 777. CrossRef
Prognostic value of interim 18F-FDG PET/CT in adult follicular lymphoma treated with R-CHOP Na Sun, Wenli Qiao, Yan Xing, Taisong Wang, Jinhua Zhao Annals of Hematology.2023; 102(4): 795. CrossRef
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients Wojciech Cytawa, Robin Hendel, Bartłomiej Tomasik, Franz-Xaver Weinzierl, Thorsten Bley, Jacek Jassem, Andreas Schirbel, Andreas K. Buck, Ralph A. Bundschuh, Philipp E. Hartrampf, Rudolf A. Werner, Constantin Lapa European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(12): 3765. CrossRef
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy Florian Rosar, Felix Wenner, Fadi Khreish, Sebastian Dewes, Gudrun Wagenpfeil, Manuela A. Hoffmann, Mathias Schreckenberger, Mark Bartholomä, Samer Ezziddin European Journal of Nuclear Medicine and Molecular Imaging.2022; 49(5): 1584. CrossRef
Prognostic significance of clinical characteristics and 18Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma Yizhen Liu, Jinjin Jiang, Lianfang Liu, Zezhou Wang, Baohua Yu, Zuguang Xia, Qunling Zhang, Dongmei Ji, Xiaojian Liu, Fangfang Lv, Xiaonan Hong, Shaoli Song, Junning Cao Journal of International Medical Research.2022;[Epub] CrossRef
Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter? Tarec Christoffer El‐Galaly, Diego Villa, Chan Yoon Cheah, Lars C. Gormsen British Journal of Haematology.2022; 197(2): 139. CrossRef
Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT Hongyan Li, Min Wang, Yajing Zhang, Fan Hu, Kun Wang, Chenyang Wang, Zairong Gao Frontiers in Oncology.2022;[Epub] CrossRef
Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma? Ross Thomas Salvaris, Chan Yoon Cheah Leukemia & Lymphoma.2022; 63(14): 3271. CrossRef
Prognostic Values of Baseline 18F‐FDG PET/CT in Patients with Peripheral T‐Cell Lymphoma Yeye Zhou, Xiaoyi Zhang, Haifeng Qin, Zixuan Zhao, Jihui Li, Bin Zhang, Shibiao Sang, Yiwei Wu, Shengming Deng, Francesco Di Raimondo BioMed Research International.2020;[Epub] CrossRef
The Incremental Prognostic Value of Baseline 18F‐FDG PET/CT Imaging in Angioimmunoblastic T‐Cell Lymphoma Hui Wang, Wenjing Yu, Tao Wu, Yangyang Xue, Dan Zhang, Huiqin Xu, Rosario Caltabiano BioMed Research International.2020;[Epub] CrossRef